{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:31:37Z","timestamp":1764873097668},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.leukres.2010.06.004","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T09:21:42Z","timestamp":1277889702000},"page":"61-65","source":"Crossref","is-referenced-by-count":5,"title":["Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhijian","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiejun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.06.004_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.leukres.2009.07.021","article-title":"Incorporating novel agents in the treatment of myelodysplastic syndrome","volume":"34","author":"Anargyrou","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.06.004_bib2","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1182\/blood-2008-09-038935","article-title":"How I treat patients with myelodysplastic syndrome","volume":"113","author":"Stone","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.06.004_bib3","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1053\/j.seminhematol.2005.05.008","article-title":"Alternative treatments for myelodysplastic syndrome","volume":"42","author":"Sekeres","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/1042819021000055345","article-title":"Immunosuppressive treatments for myelodysplastic syndrome","volume":"44","author":"Shimamoto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.06.004_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s002770100360","article-title":"Immunosuppressive therapy for patients with refractory anemia","volume":"80","author":"Asano","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-005-1016-6","article-title":"Cyclosporin A in myelodysplastic syndrome: a preliminary report","volume":"84","author":"Dixit","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0145-2126(03)00008-0","article-title":"Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan","volume":"27","author":"Shimamoto","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.06.004_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1532\/IJH97.07052","article-title":"A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(\u2212)CD59(\u2212) blood cells predicts platelet response","volume":"86","author":"Ishikawa","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Antithymocyte globulin for patients with myelodysplastic syndrome","volume":"99","author":"Molldrem","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia","volume":"120","author":"Killick","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib11","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/sj.leu.2403124","article-title":"Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndrome","volume":"17","author":"Yazji","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.06.004_bib12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndrome","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.06.004_bib13","first-page":"667","article-title":"Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndrome","volume":"91","author":"Broliden","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.06.004_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1532\/IJH97.06063","article-title":"Immunomodulatory therapy for myelodysplastic syndrome","volume":"86","author":"Sokol","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCO.0b013e3282f0e12b","article-title":"Immunomodulatory drugs in the treatment of myelodysplastic syndrome","volume":"19","author":"Ortega","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.leukres.2010.06.004_bib16","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.06.004_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndrome with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.06.004_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndrome","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.06.004_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2141.2005.05817.x","article-title":"A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndrome: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies","volume":"131","author":"Bouscary","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10428190500353943","article-title":"Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndrome","volume":"47","author":"Raza","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.06.004_bib21","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/cncr.23789","article-title":"Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndrome and acute myeloid leukemia","volume":"113","author":"Raza","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.06.004_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2008.06.005","article-title":"Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndrome","volume":"33","author":"Tamburini","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.06.004_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.06.004_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MOH.0b013e3282fa7470","article-title":"Aplastic anemia","volume":"15","author":"Young","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.leukres.2010.06.004_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hoc.2009.01.005","article-title":"Diagnosis and treatment of acquired aplastic anemia","volume":"23","author":"Bacigalupo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2010.06.004_bib26","first-page":"1610","article-title":"Cyclosporine A without or with thalidomide for the treatment of patients with myelodysplastic syndrome","volume":"26","author":"Ze-feng","year":"2006","journal-title":"Zhong Guo Shi Yong Nei Ke Za Zhi"},{"key":"10.1016\/j.leukres.2010.06.004_bib27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2010.06.004_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.leukres.2003.08.007","article-title":"Thalidomide therapy for myelodysplastic syndrome: current status and future perspectives","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.06.004_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndrome","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.06.004_bib30","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.06.004_bib31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/0003-4819-137-3-200208060-00007","article-title":"Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome","volume":"137","author":"Molldrem","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2010.06.004_bib32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.V100.5.1570.h81702001570_1570_1574","article-title":"HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome","volume":"100","author":"Saunthararajah","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.06.004_bib33","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.06.004_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","author":"Lim","year":"2007","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T08:01:25Z","timestamp":1591430485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610002961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0145212610002961"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.06.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}